Fig. 21

(Abstract P2). a Treatment scheme for B6 mice injected subcutaneously with B16-F1 melanoma tumor cells (2.5 x105) 7 days prior to lympho- 31 depletion with 6Gy total body irradiation and adoptive transfer (ACT) of 2 x106 Pmel-1 T cells (i.v.) at day 8. b Tumor growth kinetics in individual mice treated as indicated in A, (each line represents one mouse); WT (n=6), MsnKO (n=4). c Frequency of donor Pmel-1 CD8+ T cells circulating in the blood of WT and MsnKO mice from B at 8 weeks. d Survival analysis of WT and MsnKO mice upon B16 melanoma tumor injection and adoptive cell transfer. *P = 0.05 by Log-rank test (B and D), *P < 0.05 by Student’s t-test (C). Data are reported as the mean ± SEM